Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
12/2000
12/12/2000CA2023560C 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases
12/07/2000WO2000073764A2 Composition and methods for the therapeutic use of an atonal-associated sequence
12/07/2000WO2000073482A1 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
12/07/2000WO2000073450A2 Cytoskeleton-associated proteins
12/07/2000WO2000073449A1 Dna encoding snorf33 receptor
12/07/2000WO2000073445A2 Interleukin-1-receptor associated kinase-3 (irak3)
12/07/2000WO2000073324A2 Modulation of gene expression in gastrointestinal inflammation
12/07/2000WO2000073307A2 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
12/07/2000WO2000073301A1 Bicyclic oxazolidinones as antibacterial agent
12/07/2000WO2000073295A1 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides
12/07/2000WO2000073294A2 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides
12/07/2000WO2000073283A1 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
12/07/2000WO2000073279A1 4-phenyl-pyrimidine derivatives
12/07/2000WO2000073275A1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
12/07/2000WO2000073266A1 Novel antioxidants, preparation methods and uses
12/07/2000WO2000073253A1 NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-α MODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS
12/07/2000WO2000072881A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
12/07/2000WO2000072815A1 Indole derivatives
12/07/2000WO2000072801A2 Alpha v integrin receptor antagonists
12/07/2000WO2000009104A3 Use of sulfonamides for treating vision and memory disorders
12/07/2000CA2823479A1 Compositions for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
12/07/2000CA2376116A1 Promotion or inhibition of angiogenesis and cardiovascularization
12/07/2000CA2376024A1 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
12/07/2000CA2375855A1 Modulation of gene expression in gastrointestinal inflammation
12/07/2000CA2375827A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
12/07/2000CA2375348A1 Novel antioxidants, preparation methods and uses
12/07/2000CA2375186A1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
12/07/2000CA2375123A1 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
12/07/2000CA2375106A1 Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
12/07/2000CA2375047A1 Dna encoding snorf33 receptor
12/07/2000CA2374222A1 Cytoskeleton-associated proteins
12/07/2000CA2373937A1 Alpha v integrin receptor antagonists
12/07/2000CA2372233A1 Bicyclic oxazolidinones as antibacterial agent
12/07/2000CA2370598A1 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
12/06/2000EP1057813A1 Indole derivatives and medicinal compositions containing the same
12/06/2000EP1057486A1 Use of drug combination for treating Glaucoma
12/06/2000EP1057482A1 Remedy for meniere disease
12/06/2000EP1056467A2 Method for the treatment of diseases or disorders of the inner ear
12/06/2000EP1056454A1 Use of macrolide compounds for treating glaucoma
12/06/2000CN1275911A Method of preventing or treating estrogen-dependent diseases and disorders
12/05/2000US6156788 Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
12/05/2000US6156750 Bioactive bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof
12/05/2000US6156523 Serine/threonine protein kinases
12/05/2000US6156518 Methods of using DNA encoding human alpha 1 adrenergic receptors
12/05/2000US6156294 Composition and method for treatment of otitis media
12/05/2000US6156293 Moistening preparation
11/2000
11/30/2000WO2000071584A1 Seven transmembrane receptor genes
11/30/2000WO2000071560A1 Methods of modulating activity of prokaryotic ribosomes
11/30/2000WO2000071538A2 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
11/30/2000WO2000071518A2 Heterocyclic analgesic compounds and their use
11/30/2000WO2000071514A1 α-AMINO-β-SULFONYL HYDROXAMIC ACID COMPOUNDS
11/30/2000WO2000071150A1 Tumor necrosis factor receptor 5
11/30/2000WO2000071149A2 Therapeutic uses of bpi protein products in humans with otitis media with effusion
11/30/2000WO2000071140A2 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
11/30/2000WO2000071134A1 Isophosphoramide mustard analogs and use thereof
11/30/2000WO2000071107A2 New pharmaceutical combinations for nos inhibitors
11/30/2000WO2000044379A3 Methods for restoring and/or enhancing accommodation in pseudo phakia
11/30/2000WO2000043413A3 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
11/30/2000WO2000042172A3 Human homologues of proteins regulated by circadian rhythms
11/30/2000WO2000041692A3 Compositions having improved stability
11/30/2000WO2000033814A3 Method for administering agents to the central nervous system
11/30/2000WO2000024415A9 Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
11/30/2000DE19924818A1 Substituierte Phenylcyclohexancarbonsäureamide Substituted Phenylcyclohexancarbonsäureamide
11/30/2000CA2381441A1 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
11/30/2000CA2374674A1 Tumor necrosis factor receptor 5
11/30/2000CA2374668A1 New pharmaceutical combinations for nos inhibitors
11/30/2000CA2373693A1 Seven transmembrane receptor genes
11/30/2000CA2373577A1 .alpha.-amino-.beta.-sulfonyl hydroxamic acid compounds
11/30/2000CA2373262A1 Therapeutic uses of bpi protein products in humans with otitis media with effusion
11/30/2000CA2372887A1 Heterocyclic analgesic compounds and their use
11/29/2000EP1054900A1 Therapeutic uses of keratinocyte growth factor-2
11/29/2000EP1054884A1 Benzofuran-4-carboxamides and their therapeutic use
11/29/2000EP1054877A1 Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
11/29/2000EP1054871A2 Pyrimidines and triazines as integrin antagonists
11/29/2000EP1054858A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
11/29/2000EP1054857A1 Biaryl-acetic acid derivatives and their use as cox-2 inhibitors
11/29/2000EP1054679A1 Use of surface active agent for the manufacture of a medicament for treatment of disorders of the middle ear
11/29/2000EP1054662A1 Water-soluble eye drop
11/29/2000EP0655055B1 Tachykinin antagonists
11/29/2000CN1275123A Prostaglandin agonists and their use to treat bone disorders
11/29/2000CN1275078A Use of 11-(3-dimethylaminoprpylidene)-6,11-dihydrodibenz [b,e] oxepin-2-acetic acid for manufacture of medicament for treating non-allergic ophthalmic inflammatory disorders
11/28/2000US6153739 Polynucleotides encoding human uridine diphosphate galactose-4-epimerase
11/28/2000US6152142 Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
11/28/2000CA2267136C Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
11/23/2000WO2000070047A2 Full-length molecules expressed in human tissues
11/23/2000WO2000070046A2 Secreted polypeptides and corresponding polynucleotides
11/23/2000WO2000070042A1 143 human secreted proteins
11/23/2000WO2000070025A1 Methods of using rnase p reaction mechanisms of action
11/23/2000WO2000069838A1 Ion channel modulating agents
11/23/2000WO2000069824A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/23/2000WO2000069823A1 Ion channel modulating agents
11/23/2000WO2000069821A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/23/2000WO2000069431A1 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
11/23/2000WO2000069426A2 Combination of nicotinic acid or nicotinamide with riboflavin for the treatment of pruritus, itching and inflammation disorders
11/23/2000WO2000043371A3 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
11/23/2000WO2000037502A3 Vascular endothelial cell growth factor antagonists and uses thereof
11/23/2000WO2000027430A3 Composition consisting of influenza virus surface proteins and dispensing device
11/23/2000WO2000023053A3 Artificial antigen-specific cells and related methods
11/23/2000WO2000004863A3 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
11/23/2000WO1999045952A3 Method of preventing the death of retinal neurons and treating ocular diseases
1 ... 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 ... 531